<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977440</url>
  </required_header>
  <id_info>
    <org_study_id>MS 29-2020</org_study_id>
    <nct_id>NCT04977440</nct_id>
  </id_info>
  <brief_title>High Protein Intake in Critically Ill Ventilated Patients</brief_title>
  <official_title>High Protein Intake During the Early Phase of Critical Illness Compared With Normal Protein Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective interventional randomized control study was conducted on forty patients with&#xD;
      respiratory failure; all patients were intubated and mechanically ventilated for at least&#xD;
      three days. Twenty patients received high protein intake using whey protein, with daily&#xD;
      follow-up of the blood sugar level, serum electrolytes, and chemistry. ICU outcome regarding&#xD;
      food intolerance, 30-day mortality, length of MV and ICU-stay was recorded&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>Effect of high protein intake on glycemic control</measure>
    <time_frame>up to 7 days</time_frame>
    <description>measurements of blood glucose levels regularly after high protein intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of high protein intake on serum electrolytes</measure>
    <time_frame>up to 7 days</time_frame>
    <description>measurements of Na, K, Mg, phosphorous and calcium levels regularly after high protein intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of high protein intake on ICU outcome</measure>
    <time_frame>up to 7 days</time_frame>
    <description>ICU outcome includes ICU survival , mechanical ventilation , food intolerance</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Intensive Care Unit Syndrome</condition>
  <arm_group>
    <arm_group_label>standard protein</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>high protein</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey protein</intervention_name>
    <description>Patients were randomly divided into two groups: Group (A): Enteral feeding with normal protein intake ( 1.0 gm pin /kg/day ) Group (B): Enteral feeding with high protein intake ( 1.5- gm open /kg/day ) -Patient's- nonprotein- caloric intake was calculated according to REE :(25xactual body weight in kg ) and received it as follow : 1/2 the calculated amount of caloric intake in DAY 1 3/4 of the calculated amount of caloric intake in DAY 2&#xD;
-Full calculated caloric amount in DAY 3&#xD;
This regimen was followed long as the patient was tolerating the amount of feeding, and in case of intolerance:&#xD;
The volume of feeding boluses was decreased or Increase the time interval between boluses or IV metoclopramide or erythromycin was given</description>
    <arm_group_label>high protein</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult mechanically ventilated patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Mechanically ventilated patients (for three days or more )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Contraindication for enteral nutrition (gut ischemia, obstruction, or perforation)&#xD;
&#xD;
          -  Expected intolerance for enteral nutrition (paralytic ileus)&#xD;
&#xD;
          -  Inability to start enteral nutrition within 24-hours(i.e. surgery or other&#xD;
             interventions)&#xD;
&#xD;
          -  Short bowel syndrome&#xD;
&#xD;
          -  Hemodynamic instability ( i.e shock state, need for vasopressors )&#xD;
&#xD;
          -  Child C liver cirrhosis or acute liver failure&#xD;
&#xD;
          -  Dialysis dependency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>farouk faris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11345</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mostafa Farouk</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

